Session information

Poster Presentation

(E) Pharmaceutical Health Care and Sciences

[27PO7-am1] Regulatory sciences (pharmaceuticals, etc.)-2

Sun. Mar 27, 2022 9:00 AM - 10:40 AM [Room PO7] Bldgs. 3&4, 3F Passage (Bldgs. 3&4: 3F)

【説明時間】9:15～10:25

+Add all to schedule

9:00 AM - 10:40 AM

[27PO7-am1-01] Comparison of biosimilar guidelines in multi-counties/regions

○Yoshiro Saito¹, Yoshiko Aoki¹, Kimie Sai¹, Akiko Ishii-Watabe² (1. National Institute of Health Sciences, Division of Medicinal Safety Science, 2. National Institute of Health Sciences, Division of Biological Chemistry and Biologicals)

9:00 AM - 10:40 AM

[27PO7-am1-02] Clinical studies of insulin analogue and adalimumab, which have been approved by the FDA as “interchangeable products”

○Tetsu Kobayashi¹, Hiroko Shibata¹, Akiko Ishii¹ (1. NIHS)

9:00 AM - 10:40 AM

[27PO7-am1-03S] The impact of the enforcement of Guidelines for Prescription Drug Marketing Information Provision on the drug information operations of Community Healthcare Support Hospitals

○Mizuki Konosu¹, Shinichi Watanabe², Hiroki Iwata^1,3, Noriko Kobayashi^1,3, Kazuko Fujimoto¹, Katsunori Yamaura^1,3 (1. Keio Univ Faculty Pharm, 2. Teikyo Heisei Univ Pharm, 3. Keio Univ Commun Pharm)

9:00 AM - 10:40 AM

[27PO7-am1-04] Analyses of approval lags and impact on drug development periods in recently approved oncology drugs and companion diagnostics in Japan

○Akari Kotani^1,2, Hirofumi Suzuki⁴, Satoshi Toyoshima^1,5, Naomi Nagai^1,3 (1. Res. Ins. Pharm. Sci., Musashino Univ., 2. Chugai Pharmaceutical Co.,Ltd., 3. Fac. Pharm., Musashino Univ., 4. PMDA, 5. Japan Pharmacists Education Center)

9:00 AM - 10:40 AM

[27PO7-am1-05] Effects of medical service fee revision on reducing psychotropic polypharmacy

○Yusuke Okada¹, Manabu Akazawa¹ (1. Meiji Pharmaceutical Univ.)

9:00 AM - 10:40 AM

[27PO7-am1-06S] Comparison of the approval status of aniticancer drugs for pediatrics between Japan and the United State

○Toshiki Takatsuki¹, Mamoru Narukawa¹ (1. Grad. Sch. Pharm. Sci., Kitasato Univ.)

9:00 AM - 10:40 AM

[27PO7-am1-07S] Current situation of patient reported outcome evaluation in clinical trials of anticancer drugs approved in Japan

○Kanoko Watanabe¹, Saki Aino¹, Mamoru Narukawa¹ (1. School of Pharmacy, Kitasato Univ.)

9:00 AM - 10:40 AM

[27PO7-am1-08] Analysis of the relationship between safety concerns in RMP at the time of drug approval and addition to clinically significant adverse reaction in the package inserts after approval

○Rieko Saito¹, Nanae Uno¹, Yuki Kobayashi¹, Eri Hasegawa¹, Seiko Miyazaki¹ (1. Showa Pharmaceutical Univ.)

9:00 AM - 10:40 AM

[27PO7-am1-09] Analysis of the reasons for drug recalls:
towards ensuring the quality and stable supply

○Maki Matsuhama¹, Rieko Saito¹, Haruhiro Okuda², Seiko Miyazaki¹ (1. Showa Pharmaceutical Univ., 2. PMRJ)

9:00 AM - 10:40 AM

[27PO7-am1-10] Verification of hydrogen bonds between drugs inducing nausea or vomiting and 5-HTBP

○Hirohisa Doi¹, Mikie Yamato¹, Sumio Matzno², Michiko Yamamoto³, Ken-ichi Chonan¹ (1. Showa Pharm. Univ., 2. Fac. Pharm., Kindai Univ., 3. Grad. Pharm., Kumamoto Univ.)

9:00 AM - 10:40 AM

[27PO7-am1-11S] Analysis of chemical and structural characteristics of drugs associated with anaphylactic shock using the JADER and chemoinformatics

○Ryo Onishi¹, Moemi Hibino¹, Airi Ida¹, Tomoyuki Enokiya¹ (1. Suzuka Univ. Med. Sci.)

9:00 AM - 10:40 AM

[27PO7-am1-12S] Development of in silico skin sensitization prediction model using human skin sensitization data

○Jun Ito¹, Kaori Ambe¹, Takao Ashikaga², Masahiro Tohkin¹ (1. Department of Regulatory Science, Grad. Sch. Pharm. Sci., NCU, 2. Division of Risk Assessment, National Institute of Health Sciences)

Authentication

A password that applicants have been notified of is required to view abstracts.
If you are a participant and need to confirm the password, please contact us by e-mail about which annual meeting you would like to know the password for to view abstracts.
We will reply after confirming that you were a participant.
Thank you for your understanding.

Please log in with your participant account.
» Participant Log In

▲